Customize
Quick Links
Past Events

Accreditation/
Credit Designation

Physicians' Education Resource®, LLC, is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

Physicians' Education Resource®, LLC, designates this live activity for a maximum of 2.0 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Physicians' Education Resource®, LLC is approved by the California Board of Registered Nursing, Provider #16669 for 2.0 Contact Hours.

Acknowledgment of Commercial Support

This activity is supported by educational grants from Regeneron Pharmaceuticals, Inc. and Sanofi Genzyme.

Not an official event of the 2018 ASCO Annual Meeting. Not sponsored, endorsed, or accredited by ASCO, CancerLinQ, or the Conquer Cancer Foundation.

About
Accreditation
Privacy Policy
Terms & Conditions
Executive Board
Journal
Faculty Portal
Contact
Facebook
Twitter
LinkedIn
Google +
2 Clarke Drive
Suite 100
Cranbury, NJ 08512
P: 1-609-378-3701

Copyright © 2018
Physicians’ Education Resource ®, LLC.
All rights reserved.

ASCO: New Directions in Advanced Cutaneous Squamous Cell Carcinoma: Emerging Evidence of Immunotherapy

ASCO: New Directions in Advanced Cutaneous Squamous Cell Carcinoma: Emerging Evidence of Immunotherapy


Date: Saturday, June 2, 2018

Time: 7:00 PM – 9:00 PM
Dinner and registration: 6:30 PM – 7:00 PM

Location:
Hilton Chicago
International Ballroom South (Second Level)
720 South Michigan Avenue
Chicago, IL 60605

What You'll Learn:

  • The benefit of immunotherapy in advances or metastatic cSCC
  • Recently reported date that will change clinical practice
  • Multidisciplinary approaches to improve outcomes for your patients
  • Application of new cSCC data presented in Chicago

Overview:

Current treatment response rates in patients with cutaneous squamous cell carcinoma (cSCC) are suboptimal, with a minority of patients experiencing complete or partial response with present pharmacologic treatment options. Moreover, surgeries to remove cSCC tumors can be disfiguring, and your elderly patients often are not candidates for chemotherapeutic agents because they cannot tolerate the toxicities. There is clearly an unmet clinical need for improved cytoreductive strategies that may mitigate deleterious surgical outcomes in these treatment settings for your patients.

In this program, you will hear expert faculty discussing advances in immunotherapies for the treatment of advanced or metastatic cSCC, including how to translate the most recent data sets to your clinical practice, and how you can improve your role in personalized, multidisciplinary, teambased patient management. You will also learn strategies for cementing best practices for the mitigation and proactive management of treatment-related adverse events In particular, experts will provide you clinical context concerning noteworthy evidence in cancer immunotherapy, their take on how this impacts care of your patients, and how to safely apply these novel approaches.

Acknowledgment of Commercial Support

This activity is supported by educational grants from Regeneron Pharmaceuticals, Inc. and Sanofi Genzyme.

Target Audience

This educational activity is directed toward medical oncologists. Nurse practitioners, nurses, physician assistants, pharmacists, researchers, and other healthcare professionals interested in the treatment of cSCC are also invited to participate. The enduring activity will additionally be targeting those involved in the multidisciplinary care of patients with cSCC, including medical dermatologists, surgeons, head and neck cancer surgeons, and Mohs surgeons.

Learning Objectives

After successful completion of this educational activity, participants should be better able to:

  • Discuss current unmet clinical needs in the management of advanced/metastatic cSCC and evidence-based recommendations for the care of patients with these tumors
  • Determine the rationale for the development of cytoreductive strategies for the management of patients with advanced/metastatic cSCC
  • Report recent evidence concerning the use of emerging immunotherapeutic approaches for the treatment of patients with advanced or metastatic cSCC
  • Describe multidisciplinary approaches to plan for and proactively mitigate the impact of immune-related adverse events in patients who are undergoing treatment for advanced/metastatic cSCC

Program Chair:

Jason Luke, MD, FACP
Assistant Professor of Medicine
The University of Chicago Medicine
Chicago, IL

Click to see all our ASCO programs!







Become a Member

Forgot Password?
Calendar of Events
SUNMONTUESWEDTHURSFRISAT
   1234
567891011
12131415161718
19202122232425
262728293031
Filter By